Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A pediatric brain tumor consortium study

Mark W. Kieran, Roger J. Packer, Arzu Onar, Susan M. Blaney, Peter Phillips, Ian F. Pollack, J. Russell Geyer, Sri Gururangan, Anu Banerjee, Stewart Goldman, Christopher D. Turner, Jean B. Belasco, Alberto Broniscer, Yali Zhu, Emily Frank, Paul Kirschmeier, Paul Statkevich, Antoine Yver, James M. Boyett, Larry E. Kun

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: A dose-escalation phase I and pharmacokinetic study of the famesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors. Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured. Patients and Methods: Lonafarnib was administered orally twice daily at dose levels of 70, 90, 115, 150, and 200 mg/m2/dose bid. A modified continual reassessment method (CRM) was used to estimate the MTD based on actual dosages of lonafarnib administered and toxicities observed during the initial 4 weeks of treatment. Results: Fifty-three children with progressive or recurrent brain tumors were enrolled, with a median age of 12.2 years (range, 3.9 to 19.5 years). Dose-limiting pneumonitis or myelosuppression was observed in three of three patients at the 200 mg/m2/dose level. A relatively constant DLT rate at the 70, 90, and 115 mg/m2/dose levels resulted in a recommended phase II dose of 115 mg/m2/dose. Significant diarrhea did not occur with prophylactic loperamide. Both radiographic response (one anaplastic astrocytoma) and stable disease (one medulloblastoma, two high-grade and four low-grade gliomas, one ependymoma, and one sarcoma) were noted, and seven patients remained on treatment for 1 year or longer. Conclusion: Although the estimated MTD by the CRM model was 98.5 mg/m2/dose, because of the relatively constant observed DLT rate at the lower four dose levels, the recommended phase II dose of lonafarnib is 115 mg/m2/dose administered twice daily by mouth with concurrent loperamide.

Original languageEnglish (US)
Pages (from-to)3137-3143
Number of pages7
JournalJournal of Clinical Oncology
Volume25
Issue number21
DOIs
StatePublished - Jul 20 2007

Fingerprint

Farnesyltranstransferase
Central Nervous System Neoplasms
Brain Neoplasms
Pharmacokinetics
Pediatrics
Maximum Tolerated Dose
Loperamide
Prenylation
Ependymoma
Medulloblastoma
Astrocytoma
Glioma
Sarcoma
Mouth
lonafarnib
Diarrhea
Pneumonia
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method : A pediatric brain tumor consortium study. / Kieran, Mark W.; Packer, Roger J.; Onar, Arzu; Blaney, Susan M.; Phillips, Peter; Pollack, Ian F.; Geyer, J. Russell; Gururangan, Sri; Banerjee, Anu; Goldman, Stewart; Turner, Christopher D.; Belasco, Jean B.; Broniscer, Alberto; Zhu, Yali; Frank, Emily; Kirschmeier, Paul; Statkevich, Paul; Yver, Antoine; Boyett, James M.; Kun, Larry E.

In: Journal of Clinical Oncology, Vol. 25, No. 21, 20.07.2007, p. 3137-3143.

Research output: Contribution to journalArticle

Kieran, MW, Packer, RJ, Onar, A, Blaney, SM, Phillips, P, Pollack, IF, Geyer, JR, Gururangan, S, Banerjee, A, Goldman, S, Turner, CD, Belasco, JB, Broniscer, A, Zhu, Y, Frank, E, Kirschmeier, P, Statkevich, P, Yver, A, Boyett, JM & Kun, LE 2007, 'Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A pediatric brain tumor consortium study', Journal of Clinical Oncology, vol. 25, no. 21, pp. 3137-3143. https://doi.org/10.1200/JCO.2006.09.4243
Kieran, Mark W. ; Packer, Roger J. ; Onar, Arzu ; Blaney, Susan M. ; Phillips, Peter ; Pollack, Ian F. ; Geyer, J. Russell ; Gururangan, Sri ; Banerjee, Anu ; Goldman, Stewart ; Turner, Christopher D. ; Belasco, Jean B. ; Broniscer, Alberto ; Zhu, Yali ; Frank, Emily ; Kirschmeier, Paul ; Statkevich, Paul ; Yver, Antoine ; Boyett, James M. ; Kun, Larry E. / Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method : A pediatric brain tumor consortium study. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 21. pp. 3137-3143.
@article{0d8b0305673b499abec4f89d32783972,
title = "Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A pediatric brain tumor consortium study",
abstract = "Purpose: A dose-escalation phase I and pharmacokinetic study of the famesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors. Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured. Patients and Methods: Lonafarnib was administered orally twice daily at dose levels of 70, 90, 115, 150, and 200 mg/m2/dose bid. A modified continual reassessment method (CRM) was used to estimate the MTD based on actual dosages of lonafarnib administered and toxicities observed during the initial 4 weeks of treatment. Results: Fifty-three children with progressive or recurrent brain tumors were enrolled, with a median age of 12.2 years (range, 3.9 to 19.5 years). Dose-limiting pneumonitis or myelosuppression was observed in three of three patients at the 200 mg/m2/dose level. A relatively constant DLT rate at the 70, 90, and 115 mg/m2/dose levels resulted in a recommended phase II dose of 115 mg/m2/dose. Significant diarrhea did not occur with prophylactic loperamide. Both radiographic response (one anaplastic astrocytoma) and stable disease (one medulloblastoma, two high-grade and four low-grade gliomas, one ependymoma, and one sarcoma) were noted, and seven patients remained on treatment for 1 year or longer. Conclusion: Although the estimated MTD by the CRM model was 98.5 mg/m2/dose, because of the relatively constant observed DLT rate at the lower four dose levels, the recommended phase II dose of lonafarnib is 115 mg/m2/dose administered twice daily by mouth with concurrent loperamide.",
author = "Kieran, {Mark W.} and Packer, {Roger J.} and Arzu Onar and Blaney, {Susan M.} and Peter Phillips and Pollack, {Ian F.} and Geyer, {J. Russell} and Sri Gururangan and Anu Banerjee and Stewart Goldman and Turner, {Christopher D.} and Belasco, {Jean B.} and Alberto Broniscer and Yali Zhu and Emily Frank and Paul Kirschmeier and Paul Statkevich and Antoine Yver and Boyett, {James M.} and Kun, {Larry E.}",
year = "2007",
month = "7",
day = "20",
doi = "10.1200/JCO.2006.09.4243",
language = "English (US)",
volume = "25",
pages = "3137--3143",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method

T2 - A pediatric brain tumor consortium study

AU - Kieran, Mark W.

AU - Packer, Roger J.

AU - Onar, Arzu

AU - Blaney, Susan M.

AU - Phillips, Peter

AU - Pollack, Ian F.

AU - Geyer, J. Russell

AU - Gururangan, Sri

AU - Banerjee, Anu

AU - Goldman, Stewart

AU - Turner, Christopher D.

AU - Belasco, Jean B.

AU - Broniscer, Alberto

AU - Zhu, Yali

AU - Frank, Emily

AU - Kirschmeier, Paul

AU - Statkevich, Paul

AU - Yver, Antoine

AU - Boyett, James M.

AU - Kun, Larry E.

PY - 2007/7/20

Y1 - 2007/7/20

N2 - Purpose: A dose-escalation phase I and pharmacokinetic study of the famesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors. Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured. Patients and Methods: Lonafarnib was administered orally twice daily at dose levels of 70, 90, 115, 150, and 200 mg/m2/dose bid. A modified continual reassessment method (CRM) was used to estimate the MTD based on actual dosages of lonafarnib administered and toxicities observed during the initial 4 weeks of treatment. Results: Fifty-three children with progressive or recurrent brain tumors were enrolled, with a median age of 12.2 years (range, 3.9 to 19.5 years). Dose-limiting pneumonitis or myelosuppression was observed in three of three patients at the 200 mg/m2/dose level. A relatively constant DLT rate at the 70, 90, and 115 mg/m2/dose levels resulted in a recommended phase II dose of 115 mg/m2/dose. Significant diarrhea did not occur with prophylactic loperamide. Both radiographic response (one anaplastic astrocytoma) and stable disease (one medulloblastoma, two high-grade and four low-grade gliomas, one ependymoma, and one sarcoma) were noted, and seven patients remained on treatment for 1 year or longer. Conclusion: Although the estimated MTD by the CRM model was 98.5 mg/m2/dose, because of the relatively constant observed DLT rate at the lower four dose levels, the recommended phase II dose of lonafarnib is 115 mg/m2/dose administered twice daily by mouth with concurrent loperamide.

AB - Purpose: A dose-escalation phase I and pharmacokinetic study of the famesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors. Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured. Patients and Methods: Lonafarnib was administered orally twice daily at dose levels of 70, 90, 115, 150, and 200 mg/m2/dose bid. A modified continual reassessment method (CRM) was used to estimate the MTD based on actual dosages of lonafarnib administered and toxicities observed during the initial 4 weeks of treatment. Results: Fifty-three children with progressive or recurrent brain tumors were enrolled, with a median age of 12.2 years (range, 3.9 to 19.5 years). Dose-limiting pneumonitis or myelosuppression was observed in three of three patients at the 200 mg/m2/dose level. A relatively constant DLT rate at the 70, 90, and 115 mg/m2/dose levels resulted in a recommended phase II dose of 115 mg/m2/dose. Significant diarrhea did not occur with prophylactic loperamide. Both radiographic response (one anaplastic astrocytoma) and stable disease (one medulloblastoma, two high-grade and four low-grade gliomas, one ependymoma, and one sarcoma) were noted, and seven patients remained on treatment for 1 year or longer. Conclusion: Although the estimated MTD by the CRM model was 98.5 mg/m2/dose, because of the relatively constant observed DLT rate at the lower four dose levels, the recommended phase II dose of lonafarnib is 115 mg/m2/dose administered twice daily by mouth with concurrent loperamide.

UR - http://www.scopus.com/inward/record.url?scp=34547659068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547659068&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.09.4243

DO - 10.1200/JCO.2006.09.4243

M3 - Article

C2 - 17634493

AN - SCOPUS:34547659068

VL - 25

SP - 3137

EP - 3143

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -